Internal Medicine, Nephrology · Midwest City, OK
NPI
1538121421
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
9230 E Reno Ave, Suite - B
Midwest City, OK, 73130
Phone (405) 737-4900
Groups this clinician bills Medicare through
Medicare paid, 2024
$355K
9,109 services
Medicare patients, 2024
878
Average age 76
Drug cost, 2024
$1.4M
5,259 prescriptions
Company payments, 2025
$924
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wudeneh Zewdie was code 99214 (office e&m - established), 933 times for 519 patients. In total Wudeneh Zewdie billed 9,109 services in 45 codes, and Medicare paid $355K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-02-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 933 | 519 | $90.96 | $85K |
| 36415 Venipuncture Blood Collection | Office | 887 | 471 | $8.55 | $7,582 |
| 83970 Clinical Chemistry | Office | 713 | 433 | $40.02 | $29K |
| 84100 Clinical Chemistry | Office | 709 | 431 | $4.59 | $3,258 |
| 85027 Blood Count | Office | 703 | 422 | $6.26 | $4,403 |
| 82570 Clinical Chemistry | Office | 693 | 422 | $5.02 | $3,478 |
| 84156 Clinical Chemistry | Office | 692 | 421 | $3.56 | $2,461 |
| 99233 Hospital E&M - Subsequent | Facility | 605 | 224 | $95.05 | $58K |
| 80048 Clinical Chemistry | Office | 456 | 328 | $8.18 | $3,731 |
| 80053 Clinical Chemistry | Office | 371 | 329 | $10.26 | $3,805 |
| 83735 Clinical Chemistry | Office | 347 | 312 | $6.51 | $2,258 |
| 81003 Clinical Chemistry | Office | 341 | 308 | $2.18 | $743 |
| 84550 Clinical Chemistry | Office | 313 | 299 | $4.38 | $1,372 |
| 82306 Clinical Chemistry | Office | 308 | 293 | $28.69 | $8,837 |
| 99232 Hospital E&M - Subsequent | Facility | 204 | 103 | $63.39 | $13K |
By year: 2022 $393K for 9,198 services; 2023 $390K for 10,166 services; 2024 $355K for 9,109 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 887 | 471 | $8.55 | $7,582 |
| 83970 Clinical Chemistry | 713 | 433 | $40.02 | $29K |
| 84100 Clinical Chemistry | 709 | 431 | $4.59 | $3,258 |
| 85027 Blood Count | 703 | 422 | $6.26 | $4,403 |
| 82570 Clinical Chemistry | 693 | 422 | $5.02 | $3,478 |
| 84156 Clinical Chemistry | 692 | 421 | $3.56 | $2,461 |
| 80048 Clinical Chemistry | 456 | 328 | $8.18 | $3,731 |
| 80053 Clinical Chemistry | 371 | 329 | $10.26 | $3,805 |
| 83735 Clinical Chemistry | 347 | 312 | $6.51 | $2,258 |
| 81003 Clinical Chemistry | 341 | 308 | $2.18 | $743 |
Medicare prescription drug claims, 2024
In 2024, the drug Wudeneh Zewdie prescribed most often to Medicare patients was Calcitriol, with 824 prescriptions and refills. In total Wudeneh Zewdie wrote 5,259 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calcitriol Generic | 824 | 2,227 | 253 | $18K |
| Furosemide Generic | 394 | 1,051 | 135 | $3,261 |
| Farxiga Dapagliflozin Propanediol | 256 | 548 | 70 | $281K |
| Lisinopril Generic | 253 | 577 | 70 | $1,743 |
| Potassium Chloride Generic | 234 | 613 | 83 | $5,122 |
| Jardiance Empagliflozin | 214 | 399 | 49 | $236K |
| Amlodipine Besylate Generic | 210 | 519 | 71 | $1,424 |
| Ozempic Semaglutide | 173 | 259 | 42 | $252K |
| Losartan Potassium Generic | 166 | 430 | 52 | $1,731 |
| Carvedilol Generic | 125 | 338 | 41 | $1,019 |
| Atorvastatin Calcium Generic | 109 | 272 | 31 | $1,617 |
| Tamsulosin Hcl Generic | 105 | 246 | 30 | $2,593 |
| Allopurinol Generic | 89 | 263 | 26 | $782 |
| Hydralazine Hcl Generic | 80 | 187 | 25 | $901 |
| Gabapentin Generic | 72 | 181 | 22 | $1,138 |
Brand drugs: 1,076 claims; generic drugs: 4,168 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wudeneh Zewdie $924 ($924 in general payments such as food, travel and fees) from 10 companies. The largest payer was Novo Nordisk Inc with $295.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 10 | $295 |
| Vantive US Healthcare LLC | 2 | $177 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $125 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $108 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 3 | $85.33 |
| ANI Pharmaceuticals, Inc. ANIP | 2 | $45.6 |
| Akebia Therapeutics Inc AKBA | 1 | $28.71 |
| GlaxoSmithKline, LLC. GSK | 1 | $25.5 |
| Pharmacosmos Therapeutics Inc. | 1 | $19.94 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $14.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.